Biotech Co.* (Symbol)

Pharma Co. (Country)


Disclosed Funding (M)

Terms/Details (Date)

Aurora Biosciences Corp. (ABSC)

Greiner Bio-One GmbH (Austria)

Microplates and other plastic consumables


Aurora granted Greiner non-exclusive rights to develop, manufacture, market and distribute its 3,456-well NanoWell Assay Plate for use with its UHTSS platform, as well as other consumables; the companies will collaborate on the development of new products; agreement includes an up-front technology access fee, as well as royalties (11/28)

Avigen Inc. (AVGN)

Bayer AG (Germany)

Coagulin-B gene therapy for hemophilia B


Avigen will get a $15M up-front equity investment, in addition to development and manufacturing costs, milestone payments and royalties; marketing collaboration (11/16)

Carrington Laboratories Inc. (CARN)

Medline Industries Inc.

Carrington's wound and skin care products


Carrington granted Medline exclusive rights to sell and market the products; the deal is worth $50M to $60M over a five-year term, including a $12.5M consideration for royalties (11/6)

Cel-Sci Corp. (AMEX:CVM)

Orient Europharma (Taiwan)



Orient gains certain exclusive marketing rights for Multikine in Taiwan, Singapore, Hong Kong and Malaysia; it will fund clinical testing in those countries; Cel-Sci will manufacture the product; the two companies will share in revenues (11/20)

Cephalon Inc. (CEPH)

Abbott Laboratories Inc.



Abbott will transfer U.S. product rights to Gabitril to Cephalon, giving the company the right to market, sell and further develop the drug; Cephalon will pay Abbott $100M over the next four years and will make an additional payment based on the product's patent life (11/1)

Cephalon Inc. (CEPH)

Choongwae Pharma Corp. (Korea)

Provigil (modafinil)


Cephalon granted Choongwae rights to market, sell and distribute Provigil in the Republic of Korea (11/15)

Cephalon Inc. (CEPH)

Novartis Pharma AG (Switzerland)

Provigil (modafinil)


Companies will consolidate the sales and marketing efforts of four Novartis central nervous system compounds with Cephalon's Provigil for narcolepsy in the UK; Cephalon will pay Novartis about $40M and the companies will share revenues generated (11/27)

Cyanotech Corp. (CYAN)

Kyowa Engineering Co.



Cyanotech signed an agreement with Kyowa for the distribution of BioAstin in Japan; the three-year agreement calls for an up-front payment to Cyanotech and an additional payment prior to the initiation of two clinical trials (11/1)

Cytogen Corp. (CYTO)

Draxis Health Inc. (Canada)

BrachySeed implants


Cytogen will market and distribute BrachySeed implants for prostate cancer in the U.S. and Draxis will supply radioactive seed to Cytogen for sale in the U.S. under the 10-year license, distribution and supply agreement (12/6)

Genelabs Technologies Inc. (GNLB)

Watson Pharmaceuticals Inc.



Watson was granted an exclusive license for North American rights to Aslera; the companies also are joining forces on the development of indications forAslera aside from systemic lupus erythematosus; Watson will pay milestone payments and fees up to $55M, as well as royalties; Watson agreed to purchase 3M shares of Genelabs for$20.5M; the agreement also provides Watson with a five-year warrant to purchase 500,000 shares of Genelabs for $6.85 per share (11/13)

Generex Biotechnology Corp. (GNBT)

Solvay Fluorides Inc.

Solkane 134a pharma


Generex will purchase its requirements for this propellant from Solvay, which will supply it exclusively to Generex for use with pharmaceutical products delivered to the buccal cavity (10/24)

Hemosol Inc. (Canada; TSE:HML)

Dompe Farmaceutici SpA (Italy)


C$5 US$3.3

Hemosol entered into a memorandum of understanding for the marketing of Hemolink in Southern and Eastern Europe; Dompe will make a C$5M investment in Hemosol common shares at C$15 per share, and it has a 16-month option to make a further equity investment of C$5M at C$22.50 per share (10/31)

Orphan Medical Inc. (ORPH)

Kirin Brewery Co. Ltd. (Japan)

Busulfex (busulfan)


Kirin gained exclusive rights to market and distribute Busulfex injection in Asia, including Japan, China, South Korea and Taiwan (12/13)

Questcor Pharmaceuticals Inc. (AMEX:QSC)

Ahn-Gook Pharmaceuticals Inc. (South Korea)



Ahn-Gook will market Emitasol in Korea; Questcor will receive an up-front cash payment, a milestone payment and royalties on sales (12/5)

United Therapeutics Corp. (UTHR)

Antigen Pharmaceuticals Ltd. (Ireland)



Antigen will distribute UT-15 (Uniprost) in the UK and Ireland (11/16)

United Therapeutics Corp. (UTHR)

Professional Detailing Inc.



Professional Detailing will provide pre-launch and commercialization services for beraprost in the U.S. (11/2)


# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange.